Clinical trial of VP 16-213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease. A study by the cancer and leukemia group B Academic Article Article uri icon


MeSH Major

  • Alleles
  • Busulfan
  • Janus Kinase 2
  • Myeloablative Agonists
  • Polycythemia Vera


  • The epipodophyllotoxin derivative VP 16--213 (NSC 141540) was studied by the Cancer and Leukemia Group B in a broad phase II trial at three dose levels: 60 mg/m2, 90 mg/m2, and 135 mg/m2 I.V. twice weekly. No correlation between dose of VP 16--213 and response frequency in a particular disease category could be demonstrated. Of the 382 patients, 8% obtained a complete (CR) or partial remission (PR), 8% showed improvement, and 14% had stable disease. By tumor type the best responses were obtained in lymphomas (8/31 CR + PR), uterus (2/9), prostate (1/5), rhabdomyosarcoma (2/6), neuroblastoma (2/4), colon/rectum (5/81), other gastrointestinal (4/32). In lung tumors, 4/80 patients obtained CR or PR. VP 16--213 has definite antineoplastic activity but the response frequency with the twice weekly schedule may be lower than that reported with other schedules.

publication date

  • March 7, 1980



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19800115)45:2<232::AID-CNCR2820450206>3.0.CO;2-F

PubMed ID

  • 6985831

Additional Document Info

start page

  • 232

end page

  • 5


  • 45


  • 2